Use of the 40-Gene Expression Profile (40-GEP) Test in Medicare-Eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs
Main Article Content
Keywords
Adjuvant radiation therapy (ART), 40-GEP, cSCC, cost, savings
Abstract
Objective: Adjuvant radiation therapy (ART) is often recommended for high-risk cSCC patients but carries significant costs and risks. This study aims to determine if utilizing the 40-GEP test to guide ART can reduce healthcare costs in cSCC management.
Methods: Medical claims data with new diagnoses of cSCC for the 12 months ending June 2022 in the Medicare (≥65 years) population (source: IQVIA claims database) were obtained and normalized to the general population for missingness. CPT codes associated with radiation therapy within one-year post diagnosis were used to establish adjuvant RT use (defined as ‘ART’). Average weighted direct costs for four major ART modalities were calculated from published studies and (IQVIA). Sensitivity analysis was used to assess the financial impact of ART treatment using varying distributions of 40-GEP Class results.
Results: Normalized medical claims data identified 22,917 Medicare-eligible cSCC patients who received ART within the United States. The weighted average direct cost for ART, which includes the four most used CPT code-defined modalities (IGRT, IMRT, IMPT, and XRT), was $60,693 per patient, amounting to an annual projected ART cost of $1.4 billion. Using the distribution of 40-GEP results from published studies, utilization of a 40-GEP test result to avoid ART in these patients could save up to $972 million in Medicare-eligible population. Sensitivity analysis shows, depending upon the distribution of the 40-GEP results, that for every 10% of Class 2A test results omitting ART, an extra $38-66 million in annual savings is expected
Limitations: Potential limitations include a need for more comprehensive patient information and the cost of ART-related complications.
Conclusion: Utilizing the 40-GEP test results to guide ART decision-making would result in material savings to Medicare.
References
2. Ruiz ES, Kus KJB, Smile TD, et al. Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. J Am Acad Dermatol. 2022;87(1):87-94. doi:10.1016/j.jaad.2022.03.044
3. Miller J, Chang T, Schwartz D, Peters M, Baum C. Outcomes of Adjuvant Radiotherapy Following Negative Surgical Margins for Cutaneous Squamous Cell Carcinoma. Dermatol Surg. 2019 Sep;45(9):1111-1116. doi: 10.1097/DSS.0000000000001827. PMID: 30893176.
4. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Version 1.2023 — March 10, 2023 Continue Squamous Cell Skin Cancer. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
5. Likhacheva A, Awan M, Barker CA, et al. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020;10(1):8-20. doi:10.1016/j.prro.2019.10.014
6. Majeed H, Gupta V. Adverse Effects of Radiation Therapy. In: StatPearls. StatPearls Publishing; 2023. Accessed October 1, 2023. http://www.ncbi.nlm.nih.gov/books/NBK563259/
7. Wysong A, Newman JG, Covington KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2021;84(2):361-369. doi:10.1016/j.jaad.2020.04.088
8. Ibrahim SF, Kasprzak JM, Hall MA, et al. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology. 2022;18(7):833-847. doi:10.2217/fon-2021-1277
9. Singh G, Tolkachjov SN, Farberg AS. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm. Clin Cosmet Investig Dermatol. 2023;16:925-935. doi:10.2147/CCID.S403330
10. Saleeby E, Bielinski K, Fitzgerald A, Siegel J, Ibrahim S. A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC). SKIN The Journal of Cutaneous Medicine. 2022;6(6):482-496. doi:10.25251/skin.6.6.5
11. Hooper PB, Farberg AS, Fitzgerald AL, et al. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. Cancer Invest. 2022;40(10):911-922. doi:10.1080/07357907.2022.2116454
12. Farberg AS, Hall MA, Douglas L, et al. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management. Curr Med Res Opin. 2020;36(8):1301-1307. doi:10.1080/03007995.2020.1763284
13. Arron ST, Canueto J, Siegel JJ, et al. Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma (cSCC) and Benefit of Adjuvant Radiation Therapy. Fall Clinical Dermatology Conference, 2023.
14. Skin Cancer Foundation: Our New Approach to a Challenging Skin Cancer Statistic [Internet]. The Skin Cancer Foundation, 2021 [cited 2021 Jun 14]; Available from: https://www.skincancer.org/blog/our-new-approach-to-a-challenging-skin-cancer-statistic/.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.